Male Breast Cancer Treatment Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
4.5%
CAGR (2026-2032)
4 USD Bn.
Market Size
316
Report Pages
131
Market Tables
Overview
The Male Breast Cancer Treatment Market size was valued at USD 4 Billion in 2025 and the total Male Breast Cancer Treatment revenue is expected to grow at a CAGR of 3.8% from 2025 to 2032, reaching nearly USD 5.20 Billion by 2032.
Global Male Breast Cancer Treatment Market Definition:
Male breast cancer is a very rare type of cancer found among men that forms in the breast tissue of the male. It occurs when some breast cell divides rapidly forming a tumor. It can be hereditary, due to inheritance of abnormal (mutated) genes especially a gene called BRCA2. It is prevalent mostly among the elderly males, though it can occur at any age.
To know about the Research Methodology :- Request Free Sample Report
The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.
Global Male Breast Cancer Treatment Market Dynamics:
According to the American Cancer Society (ACS), 1 in 833 males is at risk of developing breast cancer. It accounts for less than 1% of all types of cancer. An increase in awareness of male breast cancer has led to the diagnosis of cancer at an early stage resulting in early and effective treatment due to which the survival rate has increased. This increase in cancer cases, evolving biotechnology, innovation in new treatments are the causes that contribute to the growth of the global male breast cancer treatment market. However, lack of an all-inclusive treatment and the high costs involved in the R&D and innovations is restraining the growth of this market.
Global Male Breast Cancer Treatment Market Segment Analysis:
Based on the type of breast cancer, Ductal Carcinoma is the most prominent type among males. This type of cancer develops in the lining of the ducts of the breast. Based on the treatment, surgery, radiation therapy, estrogen hormone therapy, chemotherapy, and targeted therapy are the popular treatments adopted for male breast cancer. Targeted therapy is relatively new and uses drugs to treat the abnormal or mutated genes in the individual and it has been proven effective and successful. Trastuzumab (Herceptin) is a drug that slows the progression of cancer by targeting HER2.
Global Male Breast Cancer Treatment Market Regional Analysis:
North America is expected to be the largest male breast cancer treatment market due to the growing geriatric population and owing to its advancement in medical sciences and biotechnology. It is also diagnosed among the younger population due to increased alcohol consumption among them. Europe is anticipated to be second in the global male breast cancer treatment market attributed to factors such as the government’s positive involvement with investment in R&D and an increase in health expenditure.
Global Male Breast Cancer Treatment Market Competitive Landscape:
The competitive landscape section in the Male Breast Cancer Treatment market offers a deep dive into the profiles of the leading players operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the companies having a stronghold in the Male Breast Cancer Treatment market. In April 2019, the US FDA has increased the use of Pfizer’s Ibrance (palbociclib) capsules in the treatment of male breast cancer.
The objective of the report is to present a comprehensive analysis of the Global Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Market dynamics, structure by analyzing the market segments and projects the Global Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth, strategies, and regional presence in the Global Market make the report investor’s guide.
Global Male Breast Cancer Treatment Market Scope: Inquire before buying
| Global Male Breast Cancer Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 4 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 4.5% | Market Size in 2032: | USD 5.20 Bn. |
| Segments Covered: | by Type | Ductal Carcinoma in Situ Paget’s Disease of the Nipple Inflammatory Breast Cancer Infiltrating Ductal carcinoma |
|
| by Treatment | Local Treatments Systemic Treatments |
||
| by Application | Mammography Biopsy Fine Needle Aspiration Biopsy Core Biopsy Excisional Biopsy PET Scan CT Scan MRI Scan Other Tests |
||
Global Male Breast Cancer Treatment Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Global Male Breast Cancer Treatment Market, Key players
1. Achieve Life Sciences Inc.
2. Pfizer
3. Eli Lilly and Company
4. Bristol-Myers Squibb Company
5. F. Hoffmann-La Roche
6. Sanofi
7. Novartis AG
8. BioNumerik Pharmaceuticals Inc.
9. Seattle Genetics Inc.
10. GlaxoSmithKline plc.
11. Teva Pharmaceutical Industries Ltd.
12. Sun Pharmaceutical Industries Ltd.
13. AstraZeneca
14. Accord Healthcare
15. Bayer AG
Frequently Asked Questions:
1. Which region has the largest share in Global Male Breast Cancer Treatment Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Market?
Ans: The Global Market is growing at a CAGR of 3.8% during forecasting period 2026-2032.
3. What is scope of the Global Market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – Achieve Life Sciences Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, Bayer AG.
5. What is the study period of this Market?
Ans: The Global Market is studied from 2025 to 2032.
Table of Contents
Global Male Breast Cancer Treatment Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Male Breast Cancer Treatment Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Male Breast Cancer Treatment Market Analysis and Forecast
6.1. Male Breast Cancer Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Male Breast Cancer Treatment Market Analysis and Forecast, By Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Male Breast Cancer Treatment Market Value Share Analysis, By Type
7.4. Male Breast Cancer Treatment Market Size (US$ Bn) Forecast, By Type
7.5. Male Breast Cancer Treatment Market Analysis, By Type
7.6. Male Breast Cancer Treatment Market Attractiveness Analysis, By Type
8. Global Male Breast Cancer Treatment Market Analysis and Forecast, By Treatment
8.1. Introduction and Definition
8.2. Key Findings
8.3. Male Breast Cancer Treatment Market Value Share Analysis, By Treatment
8.4. Male Breast Cancer Treatment Market Size (US$ Bn) Forecast, By Treatment
8.5. Male Breast Cancer Treatment Market Analysis, By Treatment
8.6. Male Breast Cancer Treatment Market Attractiveness Analysis, By Treatment
9. Global Male Breast Cancer Treatment Market Analysis and Forecast, By Diagnosis
9.1. Introduction and Definition
9.2. Key Findings
9.3. Male Breast Cancer Treatment Market Value Share Analysis, By Diagnosis
9.4. Male Breast Cancer Treatment Market Size (US$ Bn) Forecast, By Diagnosis
9.5. Male Breast Cancer Treatment Market Analysis, By Diagnosis
9.6. Male Breast Cancer Treatment Market Attractiveness Analysis, By Diagnosis
10. Global Male Breast Cancer Treatment Market Analysis, by Region
10.1. Male Breast Cancer Treatment Market Value Share Analysis, by Region
10.2. Male Breast Cancer Treatment Market Size (US$ Bn) Forecast, by Region
10.3. Male Breast Cancer Treatment Market Attractiveness Analysis, by Region
11. North America Male Breast Cancer Treatment Market Analysis
11.1. Key Findings
11.2. North America Male Breast Cancer Treatment Market Overview
11.3. North America Male Breast Cancer Treatment Market Value Share Analysis, By Type
11.4. North America Male Breast Cancer Treatment Market Forecast, By Type
11.4.1. Ductal Carcinoma in Situ
11.4.2. Paget’s Disease of the Nipple
11.4.3. Inflammatory Breast Cancer
11.4.4. Infiltrating Ductal carcinoma
11.5. North America Male Breast Cancer Treatment Market Value Share Analysis, By Treatment
11.6. North America Male Breast Cancer Treatment Market Forecast, By Treatment
11.6.1.1. Local Treatment
11.6.1.2. Systemic Treatment
11.7. North America Male Breast Cancer Treatment Market Value Share Analysis, By Diagnosis
11.8. North America Male Breast Cancer Treatment Market Forecast, By Diagnosis
11.8.1. Mammography
11.8.2. Biopsy
11.8.3. Fine Needle Aspiration Biopsy
11.8.4. Core Biopsy
11.8.5. Excisional Biopsy
11.8.6. PET Scan
11.8.7. CT Scan
11.8.8. MRI Scan
11.8.9. Other Tests
11.9. North America Male Breast Cancer Treatment Market Value Share Analysis, by Country
11.10. North America Male Breast Cancer Treatment Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Male Breast Cancer Treatment Market Analysis, by Country
11.12. U.S. Male Breast Cancer Treatment Market Forecast, By Type
11.12.1. Ductal Carcinoma in Situ
11.12.2. Paget’s Disease of the Nipple
11.12.3. Inflammatory Breast Cancer
11.12.4. Infiltrating Ductal carcinoma
11.13. U.S. Male Breast Cancer Treatment Market Forecast, By Treatment
11.13.1. Local Treatment
11.13.2. Systemic Treatment
11.14. U.S. Male Breast Cancer Treatment Market Forecast, By Diagnosis
11.14.1. Mammography
11.14.2. Biopsy
11.14.3. Fine Needle Aspiration Biopsy
11.14.4. Core Biopsy
11.14.5. Excisional Biopsy
11.14.6. PET Scan
11.14.7. CT Scan
11.14.8. MRI Scan
11.14.9. Other Tests
11.15. Canada Male Breast Cancer Treatment Market Forecast, By Type
11.15.1. Ductal Carcinoma in Situ
11.15.2. Paget’s Disease of the Nipple
11.15.3. Inflammatory Breast Cancer
11.15.4. Infiltrating Ductal carcinoma
11.16. Canada Male Breast Cancer Treatment Market Forecast, By Treatment
11.16.1. Local Treatment
11.16.2. Systemic Treatment
11.17. Canada Male Breast Cancer Treatment Market Forecast, By Diagnosis
11.17.1. Mammography
11.17.2. Biopsy
11.17.3. Fine Needle Aspiration Biopsy
11.17.4. Core Biopsy
11.17.5. Excisional Biopsy
11.17.6. PET Scan
11.17.7. CT Scan
11.17.8. MRI Scan
11.17.9. Other Tests
11.18. North America Male Breast Cancer Treatment Market Attractiveness Analysis
11.18.1. By Type
11.18.2. By Treatment
11.18.3. By Diagnosis
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Male Breast Cancer Treatment Market Analysis
12.1. Key Findings
12.2. Europe Male Breast Cancer Treatment Market Overview
12.3. Europe Male Breast Cancer Treatment Market Value Share Analysis, By Type
12.4. Europe Male Breast Cancer Treatment Market Forecast, By Type
12.4.1. Ductal Carcinoma in Situ
12.4.2. Paget’s Disease of the Nipple
12.4.3. Inflammatory Breast Cancer
12.4.4. Infiltrating Ductal carcinoma
12.5. Europe Male Breast Cancer Treatment Market Value Share Analysis, By Treatment
12.6. Europe Male Breast Cancer Treatment Market Forecast, By Treatment
12.6.1.1. Local Treatment
12.6.1.2. Systemic Treatment
12.7. Europe Male Breast Cancer Treatment Market Value Share Analysis, By Diagnosis
12.8. Europe Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.8.1. Mammography
12.8.2. Biopsy
12.8.3. Fine Needle Aspiration Biopsy
12.8.4. Core Biopsy
12.8.5. Excisional Biopsy
12.8.6. PET Scan
12.8.7. CT Scan
12.8.8. MRI Scan
12.8.9. Other Tests
12.9. Europe Male Breast Cancer Treatment Market Value Share Analysis, by Country
12.10. Europe Male Breast Cancer Treatment Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Male Breast Cancer Treatment Market Analysis, by Country
12.12. Germany Male Breast Cancer Treatment Market Forecast, By Type
12.12.1. Ductal Carcinoma in Situ
12.12.2. Paget’s Disease of the Nipple
12.12.3. Inflammatory Breast Cancer
12.12.4. Infiltrating Ductal carcinoma
12.13. Germany Male Breast Cancer Treatment Market Forecast, By Treatment
12.13.1. Local Treatment
12.13.2. Systemic Treatment
12.14. Germany Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.14.1. Mammography
12.14.2. Biopsy
12.14.3. Fine Needle Aspiration Biopsy
12.14.4. Core Biopsy
12.14.5. Excisional Biopsy
12.14.6. PET Scan
12.14.7. CT Scan
12.14.8. MRI Scan
12.14.9. Other Tests
12.15. U.K. Male Breast Cancer Treatment Market Forecast, By Type
12.15.1. Ductal Carcinoma in Situ
12.15.2. Paget’s Disease of the Nipple
12.15.3. Inflammatory Breast Cancer
12.15.4. Infiltrating Ductal carcinoma
12.16. U.K. Male Breast Cancer Treatment Market Forecast, By Treatment
12.16.1. Local Treatment
12.16.2. Systemic Treatment
12.17. U.K. Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.17.1. Mammography
12.17.2. Biopsy
12.17.3. Fine Needle Aspiration Biopsy
12.17.4. Core Biopsy
12.17.5. Excisional Biopsy
12.17.6. PET Scan
12.17.7. CT Scan
12.17.8. MRI Scan
12.17.9. Other Tests
12.18. France Male Breast Cancer Treatment Market Forecast, By Type
12.18.1. Ductal Carcinoma in Situ
12.18.2. Paget’s Disease of the Nipple
12.18.3. Inflammatory Breast Cancer
12.18.4. Infiltrating Ductal carcinoma
12.19. France Male Breast Cancer Treatment Market Forecast, By Treatment
12.19.1. Local Treatment
12.19.2. Systemic Treatment
12.20. France Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.20.1. Mammography
12.20.2. Biopsy
12.20.3. Fine Needle Aspiration Biopsy
12.20.4. Core Biopsy
12.20.5. Excisional Biopsy
12.20.6. PET Scan
12.20.7. CT Scan
12.20.8. MRI Scan
12.20.9. Other Tests
12.21. Italy Male Breast Cancer Treatment Market Forecast, By Type
12.21.1. Ductal Carcinoma in Situ
12.21.2. Paget’s Disease of the Nipple
12.21.3. Inflammatory Breast Cancer
12.21.4. Infiltrating Ductal carcinoma
12.22. Italy Male Breast Cancer Treatment Market Forecast, By Treatment
12.22.1. Local Treatment
12.22.2. Systemic Treatment
12.23. Italy Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.23.1. Mammography
12.23.2. Biopsy
12.23.3. Fine Needle Aspiration Biopsy
12.23.4. Core Biopsy
12.23.5. Excisional Biopsy
12.23.6. PET Scan
12.23.7. CT Scan
12.23.8. MRI Scan
12.23.9. Other Tests
12.24. Spain Male Breast Cancer Treatment Market Forecast, By Type
12.24.1. Ductal Carcinoma in Situ
12.24.2. Paget’s Disease of the Nipple
12.24.3. Inflammatory Breast Cancer
12.24.4. Infiltrating Ductal carcinoma
12.25. Spain Male Breast Cancer Treatment Market Forecast, By Treatment
12.25.1. Local Treatment
12.25.2. Systemic Treatment
12.26. Spain Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.26.1. Mammography
12.26.2. Biopsy
12.26.3. Fine Needle Aspiration Biopsy
12.26.4. Core Biopsy
12.26.5. Excisional Biopsy
12.26.6. PET Scan
12.26.7. CT Scan
12.26.8. MRI Scan
12.26.9. Other Tests
12.27. Rest of Europe Male Breast Cancer Treatment Market Forecast, By Type
12.27.1. Ductal Carcinoma in Situ
12.27.2. Paget’s Disease of the Nipple
12.27.3. Inflammatory Breast Cancer
12.27.4. Infiltrating Ductal carcinoma
12.28. Rest of Europe Male Breast Cancer Treatment Market Forecast, By Treatment
12.28.1. Local Treatment
12.28.2. Systemic Treatment
12.29. Rest Of Europe Male Breast Cancer Treatment Market Forecast, By Diagnosis
12.29.1. Mammography
12.29.2. Biopsy
12.29.3. Fine Needle Aspiration Biopsy
12.29.4. Core Biopsy
12.29.5. Excisional Biopsy
12.29.6. PET Scan
12.29.7. CT Scan
12.29.8. MRI Scan
12.29.9. Other Tests
12.30. Europe Male Breast Cancer Treatment Market Attractiveness Analysis
12.30.1. By Type
12.30.2. By Treatment
12.30.3. By Diagnosis
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Male Breast Cancer Treatment Market Analysis
13.1. Key Findings
13.2. Asia Pacific Male Breast Cancer Treatment Market Overview
13.3. Asia Pacific Male Breast Cancer Treatment Market Value Share Analysis, By Type
13.4. Asia Pacific Male Breast Cancer Treatment Market Forecast, By Type
13.4.1. Ductal Carcinoma in Situ
13.4.2. Paget’s Disease of the Nipple
13.4.3. Inflammatory Breast Cancer
13.4.4. Infiltrating Ductal carcinoma
13.5. Asia Pacific Male Breast Cancer Treatment Market Value Share Analysis, By Treatment
13.6. Asia Pacific Male Breast Cancer Treatment Market Forecast, By Treatment
13.6.1.1. Local Treatment
13.6.1.2. Systemic Treatment
13.7. Asia Pacific Male Breast Cancer Treatment Market Value Share Analysis, By Diagnosis
13.8. Asia Pacific Male Breast Cancer Treatment Market Forecast, By Diagnosis
13.8.1. Mammography
13.8.2. Biopsy
13.8.3. Fine Needle Aspiration Biopsy
13.8.4. Core Biopsy
13.8.5. Excisional Biopsy
13.8.6. PET Scan
13.8.7. CT Scan
13.8.8. MRI Scan
13.8.9. Other Tests
13.9. Asia Pacific Male Breast Cancer Treatment Market Value Share Analysis, by Country
13.10. Asia Pacific Male Breast Cancer Treatment Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Male Breast Cancer Treatment Market Analysis, by Country
13.12. China Male Breast Cancer Treatment Market Forecast, By Type
13.12.1. Ductal Carcinoma in Situ
13.12.2. Paget’s Disease of the Nipple
13.12.3. Inflammatory Breast Cancer
13.12.4. Infiltrating Ductal carcinoma
13.13. China Male Breast Cancer Treatment Market Forecast, By Treatment
13.13.1. Local Treatment
13.13.2. Systemic Treatment
13.14. China Male Breast Cancer Treatment Market Forecast, By Diagnosis
13.14.1. Mammography
13.14.2. Biopsy
13.14.3. Fine Needle Aspiration Biopsy
13.14.4. Core Biopsy
13.14.5. Excisional Biopsy
13.14.6. PET Scan
13.14.7. CT Scan
13.14.8. MRI Scan
13.14.9. Other Tests
13.15. India Male Breast Cancer Treatment Market Forecast, By Type
13.15.1. Ductal Carcinoma in Situ
13.15.2. Paget’s Disease of the Nipple
13.15.3. Inflammatory Breast Cancer
13.15.4. Infiltrating Ductal carcinoma
13.16. India Male Breast Cancer Treatment Market Forecast, By Treatment
13.16.1. Local Treatment
13.16.2. Systemic Treatment
13.17. India Male Breast Cancer Treatment Market Forecast, By Diagnosis
13.17.1. Mammography
13.17.2. Biopsy
13.17.3. Fine Needle Aspiration Biopsy
13.17.4. Core Biopsy
13.17.5. Excisional Biopsy
13.17.6. PET Scan
13.17.7. CT Scan
13.17.8. MRI Scan
13.17.9. Other Tests
13.18. Japan Male Breast Cancer Treatment Market Forecast, By Type
13.18.1. Ductal Carcinoma in Situ
13.18.2. Paget’s Disease of the Nipple
13.18.3. Inflammatory Breast Cancer
13.18.4. Infiltrating Ductal carcinoma
13.19. Japan Male Breast Cancer Treatment Market Forecast, By Treatment
13.19.1. Local Treatment
13.19.2. Systemic Treatment
13.20. Japan Male Breast Cancer Treatment Market Forecast, By Diagnosis
13.20.1. Mammography
13.20.2. Biopsy
13.20.3. Fine Needle Aspiration Biopsy
13.20.4. Core Biopsy
13.20.5. Excisional Biopsy
13.20.6. PET Scan
13.20.7. CT Scan
13.20.8. MRI Scan
13.20.9. Other Tests
13.21. ASEAN Male Breast Cancer Treatment Market Forecast, By Type
13.21.1. Ductal Carcinoma in Situ
13.21.2. Paget’s Disease of the Nipple
13.21.3. Inflammatory Breast Cancer
13.21.4. Infiltrating Ductal carcinoma
13.22. ASEAN Male Breast Cancer Treatment Market Forecast, By Treatment
13.22.1. Local Treatment
13.22.2. Systemic Treatment
13.23. ASEAN Male Breast Cancer Treatment Market Forecast, By Diagnosis
13.23.1. Mammography
13.23.2. Biopsy
13.23.3. Fine Needle Aspiration Biopsy
13.23.4. Core Biopsy
13.23.5. Excisional Biopsy
13.23.6. PET Scan
13.23.7. CT Scan
13.23.8. MRI Scan
13.23.9. Other Tests
13.24. Rest of Asia Pacific Male Breast Cancer Treatment Market Forecast, By Type
13.24.1. Ductal Carcinoma in Situ
13.24.2. Paget’s Disease of the Nipple
13.24.3. Inflammatory Breast Cancer
13.24.4. Infiltrating Ductal carcinoma
13.25. Rest of Asia Pacific Male Breast Cancer Treatment Market Forecast, By Treatment
13.25.1. Local Treatment
13.25.2. Systemic Treatment
13.26. Rest of Asia Pacific Male Breast Cancer Treatment Market Forecast, By Diagnosis
13.26.1. Mammography
13.26.2. Biopsy
13.26.3. Fine Needle Aspiration Biopsy
13.26.4. Core Biopsy
13.26.5. Excisional Biopsy
13.26.6. PET Scan
13.26.7. CT Scan
13.26.8. MRI Scan
13.26.9. Other Tests
13.27. Asia Pacific Male Breast Cancer Treatment Market Attractiveness Analysis
13.27.1. By Type
13.27.2. By Treatment
13.27.3. By Diagnosis
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Male Breast Cancer Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Male Breast Cancer Treatment Market Overview
14.3. Middle East & Africa Male Breast Cancer Treatment Market Value Share Analysis, By Type
14.4. Middle East & Africa Male Breast Cancer Treatment Market Forecast, By Type
14.4.1. Ductal Carcinoma in Situ
14.4.2. Paget’s Disease of the Nipple
14.4.3. Inflammatory Breast Cancer
14.4.4. Infiltrating Ductal carcinoma
14.5. Middle East & Africa Male Breast Cancer Treatment Market Value Share Analysis, By Treatment
14.6. Middle East & Africa Male Breast Cancer Treatment Market Forecast, By Treatment
14.6.1.1. Local Treatment
14.6.1.2. Systemic Treatment
14.7. Middle East & Africa Male Breast Cancer Treatment Market Value Share Analysis, By Diagnosis
14.8. Middle East & Africa Male Breast Cancer Treatment Market Forecast, By Diagnosis
14.8.1. Mammography
14.8.2. Biopsy
14.8.3. Fine Needle Aspiration Biopsy
14.8.4. Core Biopsy
14.8.5. Excisional Biopsy
14.8.6. PET Scan
14.8.7. CT Scan
14.8.8. MRI Scan
14.8.9. Other Tests
14.9. Middle East & Africa Male Breast Cancer Treatment Market Value Share Analysis, by Country
14.10. Middle East & Africa Male Breast Cancer Treatment Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Male Breast Cancer Treatment Market Analysis, by Country
14.12. GCC Male Breast Cancer Treatment Market Forecast, By Type
14.12.1. Ductal Carcinoma in Situ
14.12.2. Paget’s Disease of the Nipple
14.12.3. Inflammatory Breast Cancer
14.12.4. Infiltrating Ductal carcinoma
14.13. GCC Male Breast Cancer Treatment Market Forecast, By Treatment
14.13.1. Local Treatment
14.13.2. Systemic Treatment
14.14. GCC Male Breast Cancer Treatment Market Forecast, By Diagnosis
14.14.1. Mammography
14.14.2. Biopsy
14.14.3. Fine Needle Aspiration Biopsy
14.14.4. Core Biopsy
14.14.5. Excisional Biopsy
14.14.6. PET Scan
14.14.7. CT Scan
14.14.8. MRI Scan
14.14.9. Other Tests
14.15. South Africa Male Breast Cancer Treatment Market Forecast, By Type
14.15.1. Ductal Carcinoma in Situ
14.15.2. Paget’s Disease of the Nipple
14.15.3. Inflammatory Breast Cancer
14.15.4. Infiltrating Ductal carcinoma
14.16. South Africa Male Breast Cancer Treatment Market Forecast, By Treatment
14.16.1. Local Treatment
14.16.2. Systemic Treatment
14.17. South Africa Male Breast Cancer Treatment Market Forecast, By Diagnosis
14.17.1. Mammography
14.17.2. Biopsy
14.17.3. Fine Needle Aspiration Biopsy
14.17.4. Core Biopsy
14.17.5. Excisional Biopsy
14.17.6. PET Scan
14.17.7. CT Scan
14.17.8. MRI Scan
14.17.9. Other Tests
14.18. Rest of Middle East & Africa Male Breast Cancer Treatment Market Forecast, By Type
14.18.1. Ductal Carcinoma in Situ
14.18.2. Paget’s Disease of the Nipple
14.18.3. Inflammatory Breast Cancer
14.18.4. Infiltrating Ductal carcinoma
14.19. Rest of Middle East & Africa Male Breast Cancer Treatment Market Forecast, By Treatment
14.19.1. Local Treatment
14.19.2. Systemic Treatment
14.20. Middle East & Africa Male Breast Cancer Treatment Market Forecast, By Diagnosis
14.20.1. Mammography
14.20.2. Biopsy
14.20.3. Fine Needle Aspiration Biopsy
14.20.4. Core Biopsy
14.20.5. Excisional Biopsy
14.20.6. PET Scan
14.20.7. CT Scan
14.20.8. MRI Scan
14.20.9. Other Tests
14.21. Middle East & Africa Male Breast Cancer Treatment Market Attractiveness Analysis
14.21.1. By Type
14.21.2. By Treatment
14.21.3. By Diagnosis
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments
15. South America Male Breast Cancer Treatment Market Analysis
15.1. Key Findings
15.2. South America Male Breast Cancer Treatment Market Overview
15.3. South America Male Breast Cancer Treatment Market Value Share Analysis, By Type
15.4. South America Male Breast Cancer Treatment Market Forecast, By Type
15.4.1. Ductal Carcinoma in Situ
15.4.2. Paget’s Disease of the Nipple
15.4.3. Inflammatory Breast Cancer
15.4.4. Infiltrating Ductal carcinoma
15.5. South America Male Breast Cancer Treatment Market Value Share Analysis, By Treatment
15.6. South America Male Breast Cancer Treatment Market Forecast, By Treatment
15.6.1.1. Local Treatment
15.6.1.2. Systemic Treatment
15.7. South America Male Breast Cancer Treatment Market Value Share Analysis, By Diagnosis
15.8. South America Male Breast Cancer Treatment Market Forecast, By Diagnosis
15.8.1. Mammography
15.8.2. Biopsy
15.8.3. Fine Needle Aspiration Biopsy
15.8.4. Core Biopsy
15.8.5. Excisional Biopsy
15.8.6. PET Scan
15.8.7. CT Scan
15.8.8. MRI Scan
15.8.9. Other Tests
15.9. South America Male Breast Cancer Treatment Market Value Share Analysis, by Country
15.10. South America Male Breast Cancer Treatment Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Male Breast Cancer Treatment Market Analysis, by Country
15.12. Brazil Male Breast Cancer Treatment Market Forecast, By Type
15.12.1. Ductal Carcinoma in Situ
15.12.2. Paget’s Disease of the Nipple
15.12.3. Inflammatory Breast Cancer
15.12.4. Infiltrating Ductal carcinoma
15.13. Brazil Male Breast Cancer Treatment Market Forecast, By Treatment
15.13.1. Local Treatment
15.13.2. Systemic Treatment
15.14. Brazil Male Breast Cancer Treatment Market Forecast, By Diagnosis
15.14.1. Mammography
15.14.2. Biopsy
15.14.3. Fine Needle Aspiration Biopsy
15.14.4. Core Biopsy
15.14.5. Excisional Biopsy
15.14.6. PET Scan
15.14.7. CT Scan
15.14.8. MRI Scan
15.14.9. Other Tests
15.15. Mexico Male Breast Cancer Treatment Market Forecast, By Type
15.15.1. Ductal Carcinoma in Situ
15.15.2. Paget’s Disease of the Nipple
15.15.3. Inflammatory Breast Cancer
15.15.4. Infiltrating Ductal carcinoma
15.16. Mexico Male Breast Cancer Treatment Market Forecast, By Treatment
15.16.1. Local Treatment
15.16.2. Systemic Treatment
15.17. Mexico Male Breast Cancer Treatment Market Forecast, By Diagnosis
15.17.1. Mammography
15.17.2. Biopsy
15.17.3. Fine Needle Aspiration Biopsy
15.17.4. Core Biopsy
15.17.5. Excisional Biopsy
15.17.6. PET Scan
15.17.7. CT Scan
15.17.8. MRI Scan
15.17.9. Other Tests
15.18. Rest of South America Male Breast Cancer Treatment Market Forecast, By Type
15.18.1. Ductal Carcinoma in Situ
15.18.2. Paget’s Disease of the Nipple
15.18.3. Inflammatory Breast Cancer
15.18.4. Infiltrating Ductal carcinoma
15.19. Rest of South America Male Breast Cancer Treatment Market Forecast, By Treatment
15.19.1. Local Treatment
15.19.2. Systemic Treatment
15.20. Rest of South America Male Breast Cancer Treatment Market Forecast, By Diagnosis
15.20.1. Mammography
15.20.2. Biopsy
15.20.3. Fine Needle Aspiration Biopsy
15.20.4. Core Biopsy
15.20.5. Excisional Biopsy
15.20.6. PET Scan
15.20.7. CT Scan
15.20.8. MRI Scan
15.20.9. Other Tests
15.21. South America Male Breast Cancer Treatment Market Attractiveness Analysis
15.21.1. By Type
15.21.2. By Treatment
15.21.3. By Diagnosis
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
16.2.3.3. Integration
16.3. Company Profiles: Key Players
16.3.1. Achieve Life Sciences Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Pfizer
16.3.3. Eli Lilly and Company
16.3.4. Bristol-Myers Squibb Company
16.3.5. F. Hoffmann-La Roche
16.3.6. Sanofi
16.3.7. Novartis AG
16.3.8. BioNumerik Pharmaceuticals Inc.
16.3.9. Seattle Genetics Inc.
16.3.10. GlaxoSmithKline plc.
16.3.11. Teva Pharmaceutical Industries Ltd.
16.3.12. Sun Pharmaceutical Industries Ltd.
16.3.13. AstraZeneca
16.3.14. Accord Healthcare
16.3.15. Bayer AG
17. Primary Key Insights